MASC Trials Scientific Meeting 2026
Date: Thursday, 19 November 2026
Location: Fitzroy Ballroom, Sofitel, Melbourne, Australia
Theme: Collaborating to eliminate melanoma and skin cancer
The Melanoma and Skin Cancer Trials 2026 Scientific Meeting will bring together Australian leaders in melanoma and skin cancer clinical trials to share the latest discoveries and foster further innovative research.
Note: Registration for the MASC Trials Scientific Meeting is through the AMC website. The option to register for the Scientific Meeting only is found under Registration Items.
The 2026 Melanoma and Skin Cancer Trials Scientific Meeting is relevant to those who represent the many disciplines critical to our work, including:
- Oncologists
- Surgeons
- Radiation specialists
- Nurses
- Dermatologists
- Allied health professionals
- Health economists
- Epidemiologists
- Statisticians
- Ophthalmologists
- Research scientists
- Pathologists
- Clinical trial coordinators
- Data managers
- Consumers/patient advocates and their families
Prof Mark Shackleton is Chair of the Melanoma and Skin Cancer Trials Board of Directors. He is also Director of Oncology at Alfred Health, Co-Director of Monash Partners Comprehensive Cancer Consortium, Professor of Oncology at Monash University, Director of Cancer Trials Australia, and a Victorian Cancer Agency Clinical Research Fellow. After training in medical oncology in Melbourne, he undertook PhD studies at the Walter and Eliza Hall Institute and post-doctoral work at the University of Michigan, receiving several major prizes, including the 2012 Australian Science Minister’s Prize for Life Scientist of the Year.
Program of Speakers
Registrations open at 8:00am. Session convenor: Prof Mark Shackleton unless indicated.
Time |
Session |
|---|---|
Plenary — chaired by Prof Mark Shackleton |
|
| 8.30 – 8.40am | Open Meeting, Acknowledgement of Country — Prof Mark Shackleton |
| 8.40 – 8.50am | Gabrielle Byars — MASC Trials Operational Update |
| 8.50 – 9.05am | Welcoming Remarks by Alison Button-Sloan Nick’s Story |
| 9.05 – 9.30am | Dr Miles Andrews — Advancing the evidence base of immunotherapy related toxicity management |
| 9.30 – 9.50am | Prof Juan Su — The role of targeting lipid metabolism in the treatment of melanoma |
| 9.50 – 10.05am | Prof Michael Henderson — Melanoma Margins (MelMarT-II) – Trial Update: Progress, Insights, and Next Steps |
| 10.05 – 10.15am | Peter’s Story |
| 10.15 – 10.20am | Q & A |
| 10.20 – 11.00am |
MORNING TEA |
Clinical Trials — chaired by Prof Kiarash Khosrotehrani |
|
| 11.00 – 11.05am | Platinum Sponsor Presentation — Medison |
| 11.05 – 11.25am | Dr James Pham — NEOPECs Trial: Neoadjuvant anti-PD1 and cetuximab in cutaneous squamous cell carcinoma |
| 11.20 – 11.40am | Prof Gregory Snell — Organ transplant and Treatment Related Skin Cancer |
| 11.40am – 12.00pm | Prof Kiarash Khosrotehrani — SiroSkin Trial: Next Steps Toward Reducing Skin Cancer Burden |
| 12.00 – 12.20pm | Jane Fletcher — The Reality of Lifelong Immunosuppression: The lived experience of managing SCCs post lung transplantation |
| 12.20 – 12.25pm | Q & A |
| 12.25 – 1.45pm |
LUNCH |
Rare Cancer Clinical Trials — chaired by Prof Anthony Joshua |
|
| 1.45 – 1.50pm | Gold Sponsor Presentation — Servier |
| 1.45 – 2.05pm | A/Prof Wen Xu — I-MAT trial: Immunotherapy Merkel Adjuvant Trial |
| 2.05 – 2.25pm | Dr Malaka Ameratunga — Defining the next chapter in uveal melanoma: Evidence Gaps, Trial Design and Investigator Opportunity |
| 2.25 – 2.40pm | Carolyn and Ruth’s Story |
| 2.40 – 2.45pm | Q & A |
| 2.45 – 3.15pm |
AFTERNOON TEA |
3.15 – 3.20pm |
ACEMID — chaired by Prof Peter Soyer |
| 3.20 – 3.40pm | Jonathan Broader — Automating skin cancer screening – how do we measure success? |
| 3.40 – 4.00pm | Dr Ehsan Shamsi Gooshki — Innovative Consent Models |
| 4.00 – 4.20pm | Dr Katy Bell — Do we need a wide excision for melanoma in situ? |
| 4.20 – 4.25pm | Q & A |
4.25 – 4.30pm |
Close of Meeting — Prof Mark Shackleton |
Melanoma and Skin Cancer Trials Scientific Meeting 2026 Organising Committee
- Prof Mark Shackleton, Board Chair of Melanoma and Skin Cancer Trials, Director of Oncology at Alfred Health, Professor of Oncology at Monash University, and Director of Cancer Trials Australia
- Prof Victoria Mar, Director of the Victorian Melanoma Service at The Alfred and Adjunct Associate Professor at the School of Public Health and Preventive Medicine, Monash University
- Alison Button-Sloan, Chair, Melanoma and Skin Cancer Trials Consumer Advisory Panel
- Gabrielle Byars, CEO, Melanoma and Skin Cancer Trials
- Dr Yann Yap, Research Development Coordinator, Melanoma and Skin Cancer Trials
- Justine Robertson, Administrative Assistant
Sponsors
Sponsorship opportunities available
Melanoma and Skin Cancer Trials offers a range of benefits to sponsors of its Annual Scientific Meeting. If your company is interested in sponsoring this event, please email hello@masc.org.au for further details.
Contact
Gabrielle Byars
E: gabrielle.byars@masc.org.au
We are proud that the MASC Trials Scientific Meeting has ‘Consumers Included’ status provided by Cancer Voices, ensuring that the perspectives of patients, survivors, carers and other members of the public affected by cancer are part of the planning and program of the conference.